Corydaline ((+)-Corydaline) 是一种从Corydalis yanhusuo提取的异喹啉生物碱，是一种AChE抑制剂，IC50为 226 μM。Corydaline 是一种 μ 阿片受体 (μ-opioid receptor,Ki为 1.23 μM) 激动剂，可抑制肠道病毒 71 (EV71) 复制 (IC50为 25.23 μM)。Corydaline 具有抗血管生成，抗过敏，胃排空和抗伤害感受的作用。
| 生物活性 | Corydaline ((+)-Corydaline), an isoquinoline alkaloid isolated fromCorydalis yanhusuo, is anAChEinhibitor with anIC50of 226 μM. Corydaline is aμ-opioid receptor(Kiof 1.23 μM) agonist and inhibitsenterovirus71 (EV71)replication (IC50of 25.23 μM). Corydaline has anti-angiogenic, anti-allergic and gastric-emptying and antinociceptive activities[1][2][3]. |
| IC50& Target | AChE | μ Opioid Receptor/MOR |
|
体外研究
(In Vitro) | Corydaline (12.5-50 μM; 24 hours) treatment inhibits EV71 replication by suppressing the COX-2 expression and the phosphorylation of JNK MAPK and P38 MAPK but not ERK MAPK in vitro[2].
Corydaline could inhibit the viral RNA synthesis in a dose dependent manner[2].
Western Blot Analysis[2] | Cell Line: | Vero cells infected with EV71 | | Concentration: | 12.5 μM, 25 μM, 50 μM | | Incubation Time: | 24 hours | | Result: | Reduced the phosphorylation of P38 MAPK and JNK MAPK and the expression of COX-2. |
|
体内研究
(In Vivo) | Corydaline (10 mg/kg; subcutaneous administration; once) treatment shows antinociceptive effects in mice by significantly inhibiting the writhing behavior[3].
| Animal Model: | Male CD1 mice (30-35 g, 7-8 weeks old) injected with acetic acid[3] | | Dosage: | 10 mg/kg | | Administration: | Subcutaneous administration; once | | Result: | Showed antinociceptive effects in mice. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 结构分类 | - Alkaloids
- Isoquinoline Alkaloids
|
| 来源 | - Plants
- Papaveraceae
- Corydalis yanhusuoW. T. Wang
|
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: DMSO : 33.33 mg/mL(90.22 mM;Need ultrasonic) 配制储备液 | 1 mM | 2.7067 mL | 13.5336 mL | 27.0673 mL | | 5 mM | 0.5413 mL | 2.7067 mL | 5.4135 mL | | 10 mM | 0.2707 mL | 1.3534 mL | 2.7067 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (6.77 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 *以上所有助溶剂都可在本网站选购。
|
